# Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

> **NCT04553406** · PHASE2 · TERMINATED · sponsor: **Spero Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Mycobacterium Avium Complex
- Non-tuberculous Mycobacterium Pulmonary Disease

## Interventions

- **DRUG:** SPR720
- **DRUG:** Placebo
- **DRUG:** Open-label Standard of Care

## Key facts

- **NCT ID:** NCT04553406
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-03
- **Primary completion:** 2021-01-28
- **Final completion:** 2021-01-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Business decision pending resolution of clinical hold with FDA
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553406, "Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04553406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*